NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Report
Brokerage firm Systematix remains bullish on Jubilant Pharmova Ltd. post its June-quarter performance, with the brokerage retaining its Buy rating and target price of Rs 1,327, implying an upside of nearly 38% from the current market price of Rs 965.
The brokerage said the company's Q1 FY27 earnings were impacted by temporary supply disruptions at its Montreal facility, which affected high-margin radio pharmaceutical production.
Revenue rose 17.3% YoY to Rs 2,229 crore, broadly in line with expectations. However, Ebitda declined 14.4% YoY to Rs 248 crore, while profit after tax fell 45% YoY to Rs 56.4 crore, as margins came under pressure from supply constraints, remediation costs and lower production in the allergy immunotherapy business.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
